Stage IIIA Skin Melanoma Recruiting Phase 2 Trials for Nivolumab (DB09035)

IndicationStatusPhase
DBCOND0029533 (Stage IIIA Skin Melanoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03033576Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by SurgeryTreatment
NCT03229278Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or LymphomaTreatment